Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1LHD3)

Drug Name

N-Phenyl-1'H-phenothiazine-1'-carboxamide Drug Info

Synonyms

CHEMBL590537; N-phenyl-10H-phenothiazine-10-carboxamide; AC1LFFQA; Oprea1_595012; Oprea1_517446; MolPort-001-903-868; ZINC267871; N-phenylphenothiazine-10-carboxamide; STK067361; BDBM50308402; 10-(N'-phenylcarbamoyl)phenothiazine; N-phenylphenothiazin-10-ylcarboxamide; AKOS003441553; MCULE-6952834566; NCGC00280429-01; BAS 01095156; ST51030212; Phenothiazine-10-carboxylic acid phenylamide; N-Phenyl-1''H-phenothiazine-1''-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 777336
TTD Drug ID: DM1LHD3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hexafluronium bromide	DMFY307	Spasm	MB47.3	Approved	[2]
MEPTAZINOL	DMPSB8F	Pain	MG30-MG3Z	Approved	[3]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[4]
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[5]
Plasma derived human butyrylcholinesterase	DMF3IBC	Neurotoxicity	NE61	Phase 1	[6]
Protexia	DME1Y9W	Alzheimer disease	8A20	Phase 1	[7]
JES-9501	DMYR3IE	Alzheimer disease	8A20	Phase 1	[8]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[9]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[9]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
2	Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
3	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
4	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
5	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
6	Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
7	In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
8	Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
9	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.